Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
As previously announced, Valneva SE (NASDAQ:VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new…
Cue Health Collaborates With Pfizer To Provide People Who Test Positive For COVID-19 With Actionable Health Information To Better Inform their Treatment Journey
New educational resources will make it easier for people at high risk of progression to severe COVID-19 to protect their health through accessible and timely health information
Cue Health ("Cue")
Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its
BioVie Announces Completion Of Patient Enrollment In Phase 3 Trial Assessing NE3107 In Alzheimer’s Disease
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced
UpHealth Expects FY2023 Revenues Of $127M-$135M Vs. $177.85M Estimate
This represents growth of 5% to 12% over pro forma 2022 revenue of $121 million. For comparison purposes, both the 2023 estimated revenue and 2022 pro forma revenue include five months of
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s
The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…
Valneva Announced Additional Data From Remaining Studies And An Update On Regulatory Submissions For Its Inactivated Covid-19 Vaccine, VLA2001.
As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with
Why Inovio (INO) Shares Are Moving After-Hours
After falling initially in after-hours trading on Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are back up following the company report of worse-than-expected fourth-quarter financial results and announced topline results from REVEAL2.
INOVIO Says Phase 2 REVEAL2 Trial Evaluating VGX-3100 Did Not Meet Primary Endpoint
Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL)
Trial results did not meet the primary endpoint in
Semler Announces Clinical Study Published Using QuantaFlo As An Aid For Diagnosis Of Heart Dysfunction In The Primary Care Setting
Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers (HCPs), today announced the publication of a study in